Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Americas: Japan pledges $2.7 million to tackle Chagas:

This article was originally published in Clinica

Executive Summary

Improvements in epidemiological surveillance and research are key features of a $2.7m investment by the Japanese International Co-operation Agency (JICA) to help tackle Chagas disease in Central America. The investment will be made over five years with the aim of interrupting transmission of the disease by 2010. The move has been welcomed by the Pan American Health Organization (PAHO), which has helped co-ordinate efforts already underway in Honduras, El Salvador and Guatemala. Around 18 million people are affected by the disease across Latin America and 100 million are considered at high risk. Prophylactic control of the disease is not possible, due to the lack of a suitable vaccine, thus making diagnosis-based therapy the key to tackling the disease. Chagas poses a heavy burden on health systems: In 1998, it was considered responsible for 20% of all chronic heart disease diagnosed in Honduras.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT061397

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel